Plate Nº 36 · recorded October 10, 2026
Health & Medicine ResearchReported finding
Researchers Find 'Kill Switches' That Drive MYC Cancer Gene Amplification
Fox Chase researchers show MYC gene amplification is a regulated epigenetic process, not random mutation — and a clinically used drug can suppress it in animals.
By Nathan Brooks4 min read718 words
In brief
- MYC is dysregulated in 70% of all human malignancies and was labeled 'undruggable' for over 40 years.
- The study, published in Molecular Cell in 2026, shows MYC amplification is controlled by epigenetic proteins KDM4C and SETD2, not random mutation.
- Directing KDM4C to the MYC region alone triggered gene amplification, even in cells with normal chromosomes.
- Loss of the TP53 tumor suppressor allowed abnormal MYC amplification and tumor formation in mouse models.
- A clinically used KDM4 inhibitor successfully suppressed MYC amplification in vivo.
A 40-year-old label in cancer research — "undruggable" — may finally be cracking. Researchers at the Cancer Epigenetics Institute (CEI) at Fox Chase Cancer Center have discovered how MYC, one of the most commonly altered cancer genes, gets copied over and over inside tumors, and they showed they can stop that copying with an existing drug.
The study, published in Molecular Cell in 2026, overturns a long-standing assumption. Gene copy-number amplification — the aggressive multiplication of cancer-driving genes that fuels drug resistance — is not a random accident of genomic chaos. It is a biologically regulated process controlled by specific epigenetic machinery, meaning proteins that modify how DNA is packaged and read without changing the genetic code itself.
"For over 40 years, the MYC protein has been labeled 'undruggable' by the global scientific community due to its lack of a physical binding pocket for traditional small-molecule therapies, despite dysregulation in 70% of all human malignancies," said Johnathan R. Whetstine, Ph.D., senior author of the study, professor, and director of the CEI.
"Our lab bypassed this hurdle by targeting the DNA structural assembly line rather than the finished protein, which impacts at least 30% of cancer," Whetstine said.
What did the researchers find?
Working with human cell models, genomic analyses, and mouse studies, the team identified two chromatin-regulating proteins — KDM4C and SETD2 — that act as gatekeepers for MYC amplification.
The mechanism works like this:
- SETD2 normally keeps DNA stable and tightly regulated, blocking access to the MYC gene region.
- When SETD2 is lost or blocked, KDM4C can improperly reach the MYC gene and alter the surrounding DNA environment.
- Tumors increase KDM4C levels, and KDM4C then recruits the cell's DNA-copying machinery, forcing the MYC gene to be copied repeatedly into extra copies.
The researchers proved the link is direct, not circumstantial. Simply guiding KDM4C to the MYC region using dCas9 gene-targeting technology was enough to trigger amplification — even in cells carrying a completely normal set of chromosomes.
"These findings demonstrate that MYC amplification is not simply a random byproduct of genomic instability," said Benjamin I. Ferman, a Ph.D. student in Whetstine's lab and first author of the study. "There are specific epigenetic programs that actively control the process."
How does amplification turn aggressive?
Copying MYC is only half the story. The real danger emerges when amplified cells refuse to die.
MYC overactivation normally triggers cell death — a built-in safeguard against runaway growth. But the study found that when cells lose this fail-safe, particularly through loss of TP53, a key tumor suppressor gene, abnormal MYC amplifications can pile up to high levels and keep growing.
In mouse models, the combination of disrupted epigenetic control and TP53 loss produced high-level MYC amplification, including circular extrachromosomal DNA — free-floating rings of gene copies outside chromosomes — and ultimately tumors. Notably, the starting cells were nontransformed and caused no tumors without MYC amplification.
The findings suggest amplification develops in stages: chromatin changes first create extra MYC copies, and failing cellular defenses then let those abnormal cells survive and grow more aggressive over time. The researchers connect this relationship to the two-hit theory of cancer, which originated at Fox Chase.
Could this lead to new treatments?
The results point toward a therapeutic strategy that has long eluded oncology. Because the amplification process depends on enzymes, those enzymes become drug targets.
Blocking KDM4C activity — either genetically or with targeted drugs — reduced MYC amplification across multiple experimental systems, including MYC-amplified cancer cells and animal models. A clinically used KDM4 inhibitor successfully suppressed MYC amplification in living animals.
"MYC amplification appears to be much more dynamic and controlled than previously appreciated," Whetstine said. "That raises the possibility that these amplification states could potentially be therapeutically constrained."
The team says the work could also help identify biomarkers flagging cancers most likely to develop aggressive amplification, and inform strategies to limit tumor evolution and treatment resistance. Follow-up studies are underway at the CEI and Fox Chase.
As with any laboratory and animal research, clinical benefit remains unproven until human trials test these approaches. Still, for a gene dysregulated in 70% of human cancers, the discovery that its amplification can be switched on — and switched off — marks a significant shift in how scientists think about tumor evolution.
via Medical Xpress (Source)
More from Nathan Brooks
Nearby plates
- What Happens Within 48 Hours of Losing p53, Cancer's Guardian Gene
- Lung Cancers Evade KRAS Drugs by Switching Cell Type
- New Drug CS18 Reverses Cancer Treatment Resistance in Lab Tests
- Two-Drug Combo May Force Aggressive Kidney Cancer to Self-Destruct
- Single Molecule Reverses Prostate Cancer Drug Resistance in Lab